The 65th Annual Scientific Session & Expo of the American College of Cardiology (ACC) is almost underway.
The Cardiology Advisor will be reporting live from Chicago beginning tomorrow, April 2 through Monday, April 4. Check out our ACC 2016 meeting page for all the late-breaking clinical trial results, expert commentary, and video features.
Here’s a brief preview of the news to come each day.
Saturday, April 2
The word of the day is “prevention.” Results of the HOPE-3 trial will be announced.
During a media telebriefing, Athena Poppas, MD, FACC, ACC Scientific Session chair and director of Cardiovascular Imaging at the Cardiovascular Institute in Providence, Rhode Island, highlighted the HOPE-3 clinical trial. HOPE-3 explored intervention in patients who were low or moderate risk for cardiovascular disease. The trial was conducted in 3 countries. Women made up nearly half the study population and of the total patients, nearly half were of non-European descent.
Sunday, April 3
PCSK9 inhibitors, statins, and percutaneous coronary intervention—there’s something for everyone on Sunday.
Results from the Third DANish Study, which looked at deferred stent implantation in connection with primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction, will be presented, along with the ACCELERATE and GAUSS-3 clinical trials as well as familial hypercholesterolemia mutation status and risk for coronary artery disease.
Monday, April 4
Arrhythmia will be of particular focus on this day. Among the clinical trials and studies presented, researchers will discuss effective ablation of atrial fibrillation from the FIRE & ICE trial, rate control vs rhythm control for atrial fibrillation after cardiac surgery, and the Resuscitation Outcomes Consortium Amidarone, Lidocaine, or Placebo study.
For more information, visit the American College of Cardiology’s Scientific Sessions website.